BNGO - BioNano Genomics Inc Stock Price, Fair Value and News

0.81USD-0.05 (-5.81%)Market Closed

Market Summary

USD0.81-0.05

Market Closed

-5.81%

BNGO Stock Price

View Fullscreen

BNGO RSI Chart

BNGO Valuation

Market Cap

46.5M

Price/Earnings (Trailing)

-0.2

Price/Sales (Trailing)

1.29

EV/EBITDA

-0.13

Price/Free Cashflow

-0.37

BNGO Price/Sales (Trailing)

BNGO Profitability

EBT Margin

-643.57%

Return on Equity

-241.78%

Return on Assets

-108.44%

Free Cashflow Yield

-269.31%

BNGO Fundamentals

BNGO Revenue

Revenue (TTM)

36.1M

Rev. Growth (Yr)

30.51%

Rev. Growth (Qtr)

15.06%

BNGO Earnings

Earnings (TTM)

-232.5M

Earnings Growth (Yr)

-13.48%

Earnings Growth (Qtr)

61.01%

Breaking Down BNGO Revenue

Last 7 days

-19.0%

Last 30 days

-15.8%

Last 90 days

-30.9%

Trailing 12 Months

-90.5%

How does BNGO drawdown profile look like?

BNGO Financial Health

Current Ratio

1.4

BNGO Investor Care

Shares Dilution (1Y)

78.60%

Diluted EPS (TTM)

-6.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	29.5M	31.5M	33.6M	36.1M
2022	20.5M	23.3M	25.9M	27.8M
2021	10.5M	13.2M	15.7M	18.0M
2020	9.4M	8.4M	7.3M	8.5M
2019	12.1M	10.9M	11.4M	10.1M
2018	9.6M	10.7M	10.8M	12.0M
2017	0	0	0	9.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BioNano Genomics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 15, 2024	dixon jonathan v.	sold (taxes)	-510	1.27	-402	general counsel
Feb 15, 2024	chaubey alka	sold (taxes)	-1,372	1.27	-1,081	chief medical officer
Feb 15, 2024	oldakowski mark	sold (taxes)	-1,560	1.27	-1,229	chief operating officer
Feb 15, 2024	holmlin r. erik	sold (taxes)	-3,902	1.27	-3,073	president and ceo
Sep 18, 2023	chaubey alka	acquired	-	-	20,000	chief medical officer
Sep 18, 2023	oldakowski mark	acquired	-	-	20,000	chief operating officer
Jun 13, 2023	mamuszka hannah	bought	49,999	0.76	65,789	-
May 16, 2023	holmlin r. erik	bought	9,639	0.6426	15,000	president and ceo
May 12, 2023	oldakowski mark	sold (taxes)	-27,387	0.66	-41,496	chief operating officer
May 12, 2023	holmlin r. erik	sold (taxes)	-33,093	0.66	-50,141	president and ceo

Which funds bought or sold BNGO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	MCF Advisors LLC	new	-	12.00	12.00	-%
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-19.00	-	-%
Apr 12, 2024	DLK Investment Management, LLC	new	-	13,709	13,709	0.01%
Apr 09, 2024	Nalls Sherbakoff Group, LLC	unchanged	-	-12.00	19.00	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-22.56	-257	240	-%
Mar 11, 2024	VANGUARD GROUP INC	added	26.78	-946,690	3,578,990	-%
Mar 08, 2024	ICA Group Wealth Management, LLC	new	-	66.00	66.00	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	186	26,000	60,000	-%
Feb 16, 2024	O'Dell Group, LLC	new	-	16.00	16.00	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	new	-	164,000	164,000	0.01%

Are Funds Buying or Selling BNGO?

Are funds buying BNGO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BNGO

No. of Funds

Unveiling BioNano Genomics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.88%	1,893,645	SC 13G/A
Jul 07, 2023	blackrock inc.	2.0%	6,136,883	SC 13G/A
Feb 09, 2023	vanguard group inc	5.41%	16,064,444	SC 13G/A
Jan 30, 2023	blackrock inc.	7.8%	23,240,256	SC 13G/A
Feb 09, 2022	vanguard group inc	5.13%	14,825,634	SC 13G
Feb 04, 2022	blackrock inc.	6.5%	18,660,129	SC 13G
Feb 09, 2021	hudson bay capital management lp	1.24%	1,920,000	SC 13G/A
Jan 21, 2021	domain partners viii, l.p.	-	0	SC 13G/A
Feb 14, 2020	sio capital management, llc	4.57%	0	SC 13G/A
Jan 31, 2020	hudson bay capital management lp	7.09%	2,020,000	SC 13G

Recent SEC filings of BioNano Genomics Inc

View All Filings

Date Filed	Form Type	Document
Apr 08, 2024	8-K	Current Report
Apr 08, 2024	424B5	Prospectus Filed
Apr 05, 2024	8-K	Current Report
Mar 06, 2024	ARS	ARS
Mar 05, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	10-K	Annual Report

Peers (Alternatives to BioNano Genomics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.7B	40.1B	-5.40%	4.53%	32.1	4.58	-8.12%	-17.45%
BDX	67.1B	19.5B	-2.42%	-9.87%	53.41	3.44	4.02%	-22.04%
ALGN	22.6B	3.9B	-2.94%	-12.25%	50.69	5.84	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
HSIC	9.0B	12.3B	-4.49%	-14.03%	21.69	0.73	-2.44%	-22.68%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.34	3.18	-4.68%	82.43%
XRAY	6.3B	4.0B	-6.21%	-24.72%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-564.66	9.35	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.85	0.39	7.73%	-1066.14%
ANIK	382.1M	166.7M	0.59%	-11.05%	-4.62	2.29	6.67%	-456.34%
ANGO	253.5M	324.0M	21.04%	-28.41%	-1.32	0.78	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

BioNano Genomics Inc News

Latest updates

BioNano Genomics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	15.1%	10,721,000	9,318,000	8,662,000	7,415,000	8,215,000	7,221,000	6,670,000	5,696,000	6,302,000	4,655,000	3,856,000	3,168,000	3,989,500	2,196,000	1,182,000	1,136,000	2,789,130	3,313,000	2,175,000	1,853,000	4,013,537
Costs and Expenses	-76.4%	27,391,000	115,961,000	41,546,000	39,913,000	39,331,500	33,958,000	33,550,000	30,804,000	29,022,000	21,832,000	17,915,000	12,206,000	12,305,000	10,963,000	8,014,000	10,042,000	8,258,864	6,623,000	7,464,000	6,891,000	7,123,985
S&GA Expenses	-37.0%	15,690,500	24,896,000	26,936,000	25,976,000	25,320,500	21,216,000	21,783,000	20,277,000	19,806,500	15,327,000	13,829,000	9,528,000	9,428,000	8,659,000	5,613,000	7,368,000	5,859,876	4,449,000	5,056,000	4,791,000	4,606,698
R&D Expenses	-15.1%	11,700,500	13,785,000	14,610,000	13,937,000	14,011,000	12,742,000	11,767,000	10,527,000	9,215,500	6,505,000	4,086,000	2,678,000	2,877,000	2,304,000	2,401,000	2,674,000	2,398,891	2,174,000	2,408,000	2,100,000	2,517,287
EBITDA Margin	6.3%	-5.91	-6.31	-4.21	-4.30	-4.34	-4.39	-4.48	-4.52	-4.11	-3.65	-3.54	-3.42	-	-	-	-	-	-	-	-	-
Interest Expenses	6798.6%	4,898,000	71,000	74,000	76,000	74,500	73,000	74,000	77,000	42,000	2,000	268,000	600,000	1,068,000	589,000	561,000	761,000	731,696	578,000	645,000	273,000	266,971
Income Taxes	-192.3%	-36,000	39,000	33,000	26,000	1,805,500	28,000	41,000	9,000	-5,767,000	35,000	9,000	6,000	-11,000	30,000	5,000	5,000	7,548	4,000	5,000	5,000	9,207
Earnings Before Taxes	61.0%	-43,927,000	-112,527,000	-38,879,000	-37,098,000	-36,871,500	-31,781,000	-32,117,000	-29,943,000	-28,716,000	-20,718,000	-18,777,000	-9,941,000	-11,741,000	-10,762,000	-8,069,000	-10,505,000	-7,893,022	-6,394,000	-7,660,000	-7,847,000	-6,402,249
EBT Margin	4.0%	-6.44	-6.71	-4.59	-4.67	-4.70	-4.73	-4.78	-4.79	-4.35	-3.90	-3.88	-3.85	-	-	-	-	-	-	-	-	-
Net Income	61.0%	-43,891,000	-112,566,000	-38,912,000	-37,124,000	-38,677,000	-31,809,000	-32,158,000	-29,952,000	-22,949,000	-20,753,000	-18,786,000	-9,947,000	-11,730,000	-10,792,000	-8,074,000	-10,510,000	-7,900,000	-6,398,000	-7,665,000	-7,852,000	-6,411,457
Net Income Margin	4.8%	-6.44	-6.76	-4.65	-4.73	-4.77	-4.51	-4.54	-4.51	-4.03	-3.91	-3.88	-3.85	-	-	-	-	-	-	-	-	-
Free Cashflow	-13.3%	-29,798,000	-26,302,000	-36,977,000	-32,668,000	-34,769,000	-29,741,000	-28,600,000	-32,762,000	-25,890,000	-20,250,000	-12,471,000	-13,928,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	17.9%	214	182	271	292	308	324	322	348	377	360	357	385	60.00	41.00	27.00	19.00	30.00	19.00	25.00	30.00	25.00
Current Assets	34.0%	140	105	123	143	157	218	216	242	272	342	342	370	47.00	29.00	25.00	17.00	28.00	18.00	24.00	28.00	23.00
Cash Equivalents	-48.1%	18.00	35.00	15.00	4.00	5.00	28.00	27.00	24.00	25.00	141	333	362	38.00	19.00	17.00	8.00	17.00	8.00	15.00	21.00	17.00
Inventory	-	28.00	-	32.00	33.00	30.00	25.00	21.00	16.00	12.00	9.00	5.00	3.00	3.00	5.00	3.00	4.00	3.00	3.00	3.00	1.00	1.00
Net PPE	9.8%	23.00	21.00	20.00	19.00	18.00	16.00	14.00	13.00	10.00	9.00	6.00	6.00	5.00	4.00	3.00	2.00	2.00	1.00	1.00	2.00	2.00
Goodwill	-	-	-	77.00	77.00	77.00	56.00	56.00	56.00	56.00	7.00	7.00	7.00	7.00	7.00	-	-	-	-	-	-	-
Liabilities	88.0%	118	63.00	57.00	61.00	58.00	42.00	37.00	37.00	40.00	18.00	11.00	22.00	25.00	27.00	21.00	23.00	27.00	27.00	27.00	24.00	15.00
Current Liabilities	148.9%	100	40.00	33.00	38.00	36.00	34.00	28.00	19.00	22.00	18.00	11.00	7.00	9.00	25.00	20.00	23.00	26.00	7.00	8.00	5.00	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	15.00	16.00	2.00	2.00	-	-	19.00	19.00	18.00	9.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.00	14.00	17.00	20.00	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	15.00	16.00	2.00	2.00	-	-	19.00	19.00	18.00	9.00
Shareholder's Equity	-19.2%	96.00	119	215	231	249	282	285	311	337	342	346	363	35.00	15.00	6.00	-	4.00	-	-	6.00	10.00
Retained Earnings	-8.2%	-581	-537	-424	-385	-348	-310	-278	-246	-216	-193	-172	-153	-143	-132	-121	-113	-102	-94.68	-88.28	-80.61	-72.76
Additional Paid-In Capital	3.2%	677	656	640	618	599	594	565	559	554	535	518	516	179	147	127	109	106	87.00	87.00	86.00	83.00
Shares Outstanding	29.4%	46.00	35.00	33.00	31.00	30.00	29.00	29.00	28.00	29.00	28.00	28.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	201	-	-	-	400	-	-	-	2,045	-	-	-	27.00	-	-	-	27.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-13.3%	-29,779	-26,293	-36,709	-32,400	-34,517	-29,473	-28,332	-32,494	-25,622	-19,982	-12,419	-13,904	-12,104	-10,960	-7,218	-8,032	-9,352	-7,280	-6,316	-6,552	-4,090
Share Based Compensation	-15.5%	3,372	3,992	3,932	3,882	5,479	6,059	5,777	5,102	4,802	2,788	1,758	371	451	447	328	328	356	365	336	289	1,033
Cashflow From Investing	-265.7%	-55,373	33,427	29,576	16,528	11,610	7,953	31,240	31,964	-92,510	-185,602	74.00	-24.00	-	-2,450	-	-	-23.06	-8.00	-30.00	-	-11.83
Cashflow From Financing	444.0%	68,484	12,588	17,881	14,862	146	22,651	203	7.00	1,967	13,766	-17,158	337,536	31,686	15,083	16,268	-1,135	18,491	218	811	10,859	-32.31

BNGO Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 36,116,000	$ 27,802,000
Cost of revenue:
Total cost of revenue	26,550,000	21,857,000
Operating expenses:
Research and development	54,032,000	49,047,000
Selling, general and administrative	93,499,000	88,596,000
Goodwill impairment	77,280,000	0
Total operating expenses	224,811,000	137,643,000
Loss from operations	(215,245,000)	(131,698,000)
Other expenses
Interest income	3,311,000	1,507,000
Interest expense	(5,119,000)	(298,000)
Other income (expenses)	3,449,000	(223,000)
Loss on High Trail Agreement	(18,827,000)	0
Total other income (expense)	(17,186,000)	986,000
Loss before income taxes	(232,431,000)	(130,712,000)
Benefit (provision) for income taxes	(62,000)	(1,884,000)
Net loss	$ (232,493,000)	$ (132,596,000)
Net loss per share, basic (in dollars per share)	$ (6.81)	$ (4.58)
Net loss per share, diluted (in dollars per share)	$ (6.81)	$ (4.58)
Weighted-average common shares outstanding, basic (in shares)	34,150	28,921
Weighted-average common shares outstanding, diluted (in shares)	34,150	28,921
Product revenue
Revenue:
Total revenue	$ 26,727,000	$ 20,425,000
Cost of revenue:
Total cost of revenue	20,415,000	15,966,000
Service and other revenue
Revenue:
Total revenue	9,389,000	7,377,000
Cost of revenue:
Total cost of revenue	$ 6,135,000	$ 5,891,000

BNGO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 17,948	$ 5,091
Investments	48,823	108,095
Accounts receivable, net	9,319	7,022
Inventory	22,892	29,761
Prepaid expenses and other current assets	6,019	7,329
Restricted investments	35,117	0
Total current assets	140,118	157,298
Restricted cash	400	400
Property and equipment, net	23,345	18,029
Operating lease right-of-use assets	5,633	7,222
Finance lease right-of-use assets	3,503	3,707
Intangible assets, net	33,974	41,143
Goodwill	0	77,289
Other long-term assets	7,431	2,414
Total assets	214,404	307,502
Current liabilities:
Accounts payable	10,384	12,534
Accrued expenses	8,089	10,552
Contract liabilities	783	871
Operating lease liability	2,163	2,260
Finance lease liability	272	285
Contingent consideration	0	9,382
Purchase option liability (at fair value)	8,534	0
Convertible notes payable (at fair value)	69,803	0
Total current liabilities	100,028	35,884
Operating lease liability, net of current portion	3,590	5,504
Finance lease liability, net of current portion	3,585	3,619
Contingent consideration, net of current portion	10,890	12,970
Long-term contract liabilities	154	127
Total liabilities	118,247	58,104
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value, 400,000,000 shares authorized at December 31, 2023 and 2022; 45,752,000 and 29,718,000 shares issued and outstanding at December 31, 2023 and 2022, respectively	5	3
Additional paid-in capital	677,337	599,234
Accumulated deficit	(581,208)	(348,715)
Accumulated other comprehensive income (loss)	23	(1,124)
Total stockholders’ equity	96,157	249,398
Total liabilities and stockholders’ equity	$ 214,404	$ 307,502

About BioNano Genomics Inc

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

CEO	Dr. Robert Erik Holmlin M.B.A., Ph.D.
WEBSITE	https://bionano.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	405

BioNano Genomics Inc Frequently Asked Questions

What is the ticker symbol for BioNano Genomics Inc? What does BNGO stand for in stocks?

BNGO is the stock ticker symbol of BioNano Genomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioNano Genomics Inc (BNGO)?

As of Tue Apr 16 2024, market cap of BioNano Genomics Inc is 46.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BNGO stock?

You can check BNGO's fair value in chart for subscribers.

What is the fair value of BNGO stock?

You can check BNGO's fair value in chart for subscribers. The fair value of BioNano Genomics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioNano Genomics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BNGO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioNano Genomics Inc a good stock to buy?

The fair value guage provides a quick view whether BNGO is over valued or under valued. Whether BioNano Genomics Inc is cheap or expensive depends on the assumptions which impact BioNano Genomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BNGO.

What is BioNano Genomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, BNGO's PE ratio (Price to Earnings) is -0.2 and Price to Sales (PS) ratio is 1.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BNGO PE ratio will change depending on the future growth rate expectations of investors.